Citigroup Inc. Boosts Holdings in Moderna, Inc. (NASDAQ:MRNA)

Citigroup Inc. boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 30.5% in the third quarter, Holdings Channel.com reports. The fund owned 591,910 shares of the company’s stock after buying an additional 138,378 shares during the quarter. Citigroup Inc.’s holdings in Moderna were worth $39,557,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of MRNA. Intrinsic Value Partners LLC grew its position in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after acquiring an additional 24,505 shares during the last quarter. Banco Santander S.A. purchased a new position in Moderna during the 3rd quarter worth $3,550,000. John G Ullman & Associates Inc. grew its position in Moderna by 341.3% during the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after purchasing an additional 38,400 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after purchasing an additional 167,596 shares during the period. Finally, Vontobel Holding Ltd. raised its holdings in shares of Moderna by 148.2% in the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after buying an additional 69,313 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Moderna from a “sell” rating to a “hold” rating and lowered their price target for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Royal Bank of Canada restated a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. Barclays lowered their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. The Goldman Sachs Group cut their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Finally, Bank of America lowered their target price on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $84.00.

Moderna Trading Up 7.5 %

NASDAQ:MRNA opened at $41.11 on Monday. Moderna, Inc. has a 52-week low of $35.80 and a 52-week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $54.96 and a 200-day simple moving average of $93.90. The company has a market capitalization of $15.82 billion, a PE ratio of -7.06 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.39) earnings per share. On average, equities research analysts expect that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 2,930 shares of company stock valued at $217,170. 15.70% of the stock is owned by corporate insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.